902TiP COMPOSE: Pivotal phase III trial to compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumours
| Autor: | Halfdanarson, T.R., Halperin, D., Reidy-Lagunes, D., Kong, G., Mailman, J., Herrmann, K., Sri Rajaskanthan, R., Leyden, S., Capdevila Castillon, J., Sierras, C., Harris, P. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S960-S960 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|